Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2005

01-07-2005 | Report

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group

Authors: George Fountzilas, Dimitrios Pectasides, Anna Kalogera-Fountzila, Dimosthenis Skarlos, Haralambos P. Kalofonos, Christos Papadimitriou, Dimitrios Bafaloukos, Stefanos Lambropoulos, Savvas Papadopoulos, Helen Kourea, Christos Markopoulos, Helen Linardou, Dimitrios Mavroudis, Evangelos Briasoulis, Nicholaos Pavlidis, Evangelia Razis, Paraskevas Kosmidis, Helen Gogas

Published in: Breast Cancer Research and Treatment | Issue 1/2005

Login to get access
Metadata
Title
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group
Authors
George Fountzilas
Dimitrios Pectasides
Anna Kalogera-Fountzila
Dimosthenis Skarlos
Haralambos P. Kalofonos
Christos Papadimitriou
Dimitrios Bafaloukos
Stefanos Lambropoulos
Savvas Papadopoulos
Helen Kourea
Christos Markopoulos
Helen Linardou
Dimitrios Mavroudis
Evangelos Briasoulis
Nicholaos Pavlidis
Evangelia Razis
Paraskevas Kosmidis
Helen Gogas
Publication date
01-07-2005
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-0322-y

Other articles of this Issue 1/2005

Breast Cancer Research and Treatment 1/2005 Go to the issue

Report

Long-term dysregulation of circadian and 17-β estradiol-induced LH, prolactinand corticosterone secretion after dimethylbenz (a) anthracene administrationin the Sprague–Dawley female rat

Letter to the editor

Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?

Clinical trial

Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer

Brief Communication

The S-phase fraction of the aneuploid cell subpopulation is the biologically relevant one in aneuploid breast cancers

Report

Soyfood intake and breast cancer survival: a followup of the Shanghai Breast Cancer Study

Brief Communication

Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits